Navigation Links
KemPharm Continues to Expand its Pain Therapy Pipeline with Discovery of KP606, a Novel Prodrug of Oxycodone
Date:9/4/2013

NORTH LIBERTY, Iowa and LAS VEGAS, Sept. 4, 2013 /PRNewswire/ -- KemPharm, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of new, safer therapies to treat pain, today announced the advancement of a new pain therapy program, KP606, a first-in-class oral prodrug of oxycodone.  KP606 adds to the Company's franchise of abuse-deterrent prodrugs, which includes KP201 (hydrocodone) and KP511 (hydromorphone).

KemPharm announced the discovery of KP606 at PAINWeek 2013, the nation's largest pain conference for frontline clinicians with an interest in pain management.  

In preclinical studies, KP606 exhibited superior pharmacological characteristics that suggest an improved safety profile compared to currently marketed oxycodone products, possibly reducing or preventing symptoms of constipation and limiting abuse potential. KP606 also features tamper resistant properties that make it difficult to extract oxycodone from the prodrug, which is not active until cleaved in the body.

Travis C. Mickle, Ph.D., President and CEO of KemPharm, commented, "With the discovery of KP606, KemPharm now has the most complete – and advanced – pipeline of abuse-deterrent opioid prodrugs in development. Oxycodone, along with hydrocodone and hydromorphone, are not only the most prescribed opioid-based pain medications, but are three of the most prescribed drugs in the entire world.  As we continue towards an NDA filing for KP201 in the second quarter of 2014, KemPharm's goal is to re-define the pain management market by developing a franchise of therapeutics that offer unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation."

About KemPharmKemPharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (NCEs) to treat serious medical conditions through its proprietary and broadly applicable Ligand Activated Therapy (LAT) approach.  The company utilizes its LAT technology to generate improved prodrug versions of FDA approved drugs in the high needs areas of pain, ADHD and other CNS diseases.  KemPharm's lead clinical candidate, KP201, is in development for the treatment of acute, moderate to moderately severe pain with a new drug application (NDA) expected to be filed in the second quarter of 2014. Composed of hydrocodone chemically bound to a ligand, KP201 offers unique physicochemical and pharmacological attributes that may deliver additional patient benefits, including reduced potential for abuse and reduction or elimination of opioid-induced constipation (OIC). KemPharm's pipeline is also highlighted by KP511, its hydromorphone prodrug for pain, KP606, its oxycodone prodrug for pain, and KP415, a prodrug of methylphenidate for the treatment of ADHD.  For more information on KemPharm, please visit the company's website at www.kempharm.comFor KemPharm, Inc:

Media / Investor Contacts:Christal Mickle

Jason Rando / Joshua Drumm, Ph.D. 319-665-2575 

Tiberend Strategic Advisors, Inc.info@kempharm.com 

212.827.0020jrando@tiberend.comjdrumm@tiberend.com


'/>"/>
SOURCE KemPharm, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. KemPharms KP201 to be Featured at PAINWeek 2013
2. KemPharms KP201 Demonstrates Complete Metabolic Cleavage of Prodrug and Steady-State Pharmacokinetic Profiles for Hydrocodone, Hydromorphone and Acetaminophen
3. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
4. KemPharm Advances KP201 Clinical and Commercial Program with Completion of Tablet Registration Activities
5. KemPharm Supports Recent FDA Recommendations for Hydrocodone-Containing Compounds and Abuse-Deterrent Opioids
6. Device Sector Facing Medical Education Challenges as Industry Continues Expansion into Emerging Markets
7. Americas Obsession with New "Anti-Aging" Pill Continues
8. Emdeon Continues Focus on Patient-Centered Healthcare Solutions; Renews Chain Drug Consortium Contract for Multiple Pharmacy Solutions
9. The Kenneth Rainin Foundation Continues its Commitment to Ending Inflammatory Bowel Disease, Awarding $1.5 Million in Research Grants
10. CAO Group Continues to Lead Innovation With launch of New, High Technology Turbo Forensic Light System
11. American Pacific Board Continues Focus On Corporate Governance With Appointment Of Independent Lead Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/25/2017)... , Sept. 25, 2017   Montrium ... Master File solutions, today—from the IQPC Trial Master ... , NL)—announced that EastHORN Clinical Services has ... clinical programs and TMF management. EastHORN, a leading ... eTMF platform to increase transparency to enable greater ...
(Date:9/19/2017)... a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that uses pulsed ...   ... Jim Bertolina, ... Tom Tefft ... medical device executive Josh Stopek , PhD, who has led R&D and business development ...
(Date:9/12/2017)... NEW YORK , Sept. 12, 2017   EcoVadis ... global supply chains, has published the first annual edition of its Global ... more than 20,400 companies evaluated by EcoVadis, based on Scorecard Ratings that ... ... Risk & Performance Index ...
Breaking Medicine Technology:
(Date:10/13/2017)... NJ (PRWEB) , ... October 13, 2017 , ... Global ... at scenic Alexandria Park in Milford, NJ. This free event, sponsored by Global ... physical activity. The fun run is geared towards children of all ages; it ...
(Date:10/13/2017)... ... ... “The Journey: From the Mountains to the Mission Field”: the story of ... Philippines. “The Journey: From the Mountains to the Mission Field” is the creation of ... taught all ages and currently teaches a class of ladies at her church, which ...
(Date:10/12/2017)... ... ... Planet Fitness, one of the largest and fastest growing franchisors and operators ... location in Covington, LA at 401 N. U.S. Highway 190, in January of 2018. ... in the Holiday Square shopping center. Its location allows it to serve both Covington ...
(Date:10/12/2017)... ... 12, 2017 , ... Asante, a nationally recognized health system ... their existing home health joint venture through an agreement, effective October 1, 2017, ... venture home health company with Asante, delivering clinically integrated care, for the past ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... Leading pediatric ... peers in Washington, D.C., for the 49th Congress of the International Society of ... Vice President of the Center for Cancer and Blood Disorders at Children’s ...
Breaking Medicine News(10 mins):